Epratuzumab: Difference between revisions
Content deleted Content added
m Added link to corresponding ligand page on the IUPHAR/BPS Guide to PHARMACOLOGY |
→top: Both phase III trials (EMBODY1/2) for SLE failed ... <ref |
||
| Line 51: | Line 51: | ||
'''Epratuzumab''' (planned trade name '''LymphoCide''') is a [[humanized monoclonal antibody]]. Potential uses may be found in [[oncology]] and in treatment of [[inflammation|inflammatory]] [[autoimmune disorder]]s, such as [[systemic lupus erythematosus]] (SLE).<ref>[http://clincancerres.aacrjournals.org/cgi/content/full/9/10/3982S Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties] Clinical Cancer Research Vol. 9, September 1, 2003 ''free full text''</ref><ref>[http://clincancerres.aacrjournals.org/cgi/content/full/11/14/5215 Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab] Clinical Cancer Research Vol. 11, July 15, 2005 ''free full text''</ref> The manufacturers in August 2009 announced success in early trials against SLE,<ref>Reuters: [http://www.reuters.com/article/pressRelease/idUS59586+27-Aug-2009+GNW20090827 UCB and Immunomedics Announce Positive Results for Epratuzumab Phase IIb Study in Systemic Lupus Erythematosus (SLE)]</ref> and the drug is in [[Phase III clinical trial]]s {{as of|2014|2|lc=on}}.<ref name="Spreitzer">{{cite journal| author = H. Spreitzer| date = 3 February 2014| title = Neue Wirkstoffe – Epratuzumab| journal = Österreichische Apothekerzeitung| issue = 3/2014| page = 28| language = German}}</ref> |
'''Epratuzumab''' (planned trade name '''LymphoCide''') is a [[humanized monoclonal antibody]]. Potential uses may be found in [[oncology]] and in treatment of [[inflammation|inflammatory]] [[autoimmune disorder]]s, such as [[systemic lupus erythematosus]] (SLE).<ref>[http://clincancerres.aacrjournals.org/cgi/content/full/9/10/3982S Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties] Clinical Cancer Research Vol. 9, September 1, 2003 ''free full text''</ref><ref>[http://clincancerres.aacrjournals.org/cgi/content/full/11/14/5215 Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab] Clinical Cancer Research Vol. 11, July 15, 2005 ''free full text''</ref> The manufacturers in August 2009 announced success in early trials against SLE,<ref>Reuters: [http://www.reuters.com/article/pressRelease/idUS59586+27-Aug-2009+GNW20090827 UCB and Immunomedics Announce Positive Results for Epratuzumab Phase IIb Study in Systemic Lupus Erythematosus (SLE)]</ref> and the drug is in [[Phase III clinical trial]]s {{as of|2014|2|lc=on}}.<ref name="Spreitzer">{{cite journal| author = H. Spreitzer| date = 3 February 2014| title = Neue Wirkstoffe – Epratuzumab| journal = Österreichische Apothekerzeitung| issue = 3/2014| page = 28| language = German}}</ref> |
||
July 2015 : Both phase III trials (EMBODY1/2) for SLE failed to meet primary endpoint.<ref name=SA201507>[http://seekingalpha.com/news/2662465-epratuzumab-flunks-two-phase-3-studies-immunomedics-plummets-42-percent-premarket Epratuzumab flunks two Phase 3 studies; Immunomedics plummets 42% premarket. July 28 2015]</ref> |
|||
==Mechanism of action== |
==Mechanism of action== |
||
Revision as of 07:53, 1 August 2015
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD22 |
| Clinical data | |
| Trade names | LymphoCide |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Epratuzumab (planned trade name LymphoCide) is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE).[1][2] The manufacturers in August 2009 announced success in early trials against SLE,[3] and the drug is in Phase III clinical trials as of February 2014[update].[4]
July 2015 : Both phase III trials (EMBODY1/2) for SLE failed to meet primary endpoint.[5]
Mechanism of action
Epratuzumab binds to the glycoprotein CD22 of mature and malignant B-cells.
References
- ^ Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties Clinical Cancer Research Vol. 9, September 1, 2003 free full text
- ^ Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab Clinical Cancer Research Vol. 11, July 15, 2005 free full text
- ^ Reuters: UCB and Immunomedics Announce Positive Results for Epratuzumab Phase IIb Study in Systemic Lupus Erythematosus (SLE)
- ^ H. Spreitzer (3 February 2014). "Neue Wirkstoffe – Epratuzumab". Österreichische Apothekerzeitung (in German) (3/2014): 28.
- ^ Epratuzumab flunks two Phase 3 studies; Immunomedics plummets 42% premarket. July 28 2015
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |